Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 11 09 2019
revised: 28 02 2020
accepted: 02 04 2020
pubmed: 9 4 2020
medline: 18 11 2020
entrez: 9 4 2020
Statut: ppublish

Résumé

Myeloid-derived suppressor cells (MDSC) include immature monocytic (M-MDSC) and granulocytic (PMN-MDSC) cells that share the ability to suppress adaptive immunity and to hinder the effectiveness of anticancer treatments. Of note, in response to IFNγ, M-MDSCs release the tumor-promoting and immunosuppressive molecule nitric oxide (NO), whereas macrophages largely express antitumor properties. Investigating these opposing activities, we found that tumor-derived prostaglandin E2 (PGE2) induces nuclear accumulation of p50 NF-κB in M-MDSCs, diverting their response to IFNγ toward NO-mediated immunosuppression and reducing TNFα expression. At the genome level, p50 NF-κB promoted binding of STAT1 to regulatory regions of selected IFNγ-dependent genes, including inducible nitric oxide synthase (Nos2). In agreement, ablation of p50 as well as pharmacologic inhibition of either the PGE2 receptor EP2 or NO production reprogrammed M-MDSCs toward a NOS2

Identifiants

pubmed: 32265223
pii: 0008-5472.CAN-19-2843
doi: 10.1158/0008-5472.CAN-19-2843
doi:

Substances chimiques

NF-kappa B p50 Subunit 0
NFKB1 protein, human 0
Oxytocics 0
Nitric Oxide 31C4KY9ESH
Interferon-gamma 82115-62-6
Dinoprostone K7Q1JQR04M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2874-2888

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Chiara Porta (C)

Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.
Center for Translational Research on Autoimmune & Allergic Diseases (CAAD) Cso Trieste 15/A, Novara, Italy.

Francesca Maria Consonni (FM)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Sara Morlacchi (S)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Sabina Sangaletti (S)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Augusto Bleve (A)

Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.

Maria Grazia Totaro (MG)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Paola Larghi (P)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Monica Rimoldi (M)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Claudio Tripodo (C)

Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy.

Laura Strauss (L)

Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.

Stefania Banfi (S)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Mariangela Storto (M)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Tiziana Pressiani (T)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Lorenza Rimassa (L)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Silvia Tartari (S)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Alessandro Ippolito (A)

Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.

Andrea Doni (A)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Giulia Soldà (G)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Stefano Duga (S)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Viviana Piccolo (V)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Renato Ostuni (R)

San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.

Gioacchino Natoli (G)

Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Vincenzo Bronte (V)

Department of Medicine, Verona University Hospital, Verona, Italy.

Fiorella Balzac (F)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.

Emilia Turco (E)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.

Emilio Hirsch (E)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.

Mario P Colombo (MP)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Antonio Sica (A)

Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy. antonio.sica@uniupo.it.
Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH